Obesity diminishes response to PD-1-based immunotherapies in renal cancer.
Shannon K BoiRachael M OrlandellaJustin Tyler GibsonWilliam James TurbittGal WaldLewis ThomasClaire Buchta RoseanKatlyn E NorrisMegan BingLaura BertrandBrett P GrossAmani MakkoukDmytro StarenkiKristine I FaragRobert E SorgeJames A BrownJennifer GordetskyHesham YasinRohan GarjeLakshminarayanan NandagopalGeorge J WeinerDavid M LubaroffRebecca C ArendPeng LiYousef ZakhariaEddy YangAliasger K SalemKenneth NeppleTatiana T Marquez-LagoLyse A NorianPublished in: Journal for immunotherapy of cancer (2021)
We find that obesity is associated with diminished efficacy of anti-PD-1-based therapies in renal cancer, due in part to increased inflammatory IL-1β levels, highlighting the need for continued study of this critical issue.